CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Clene Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.29+0.19 (+6.13%)
Close on Oct 19, 2026
- Market cap
- $40.74M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
78.5%
Operating margin
-11541.5%−1728.9 pts over 5 years
Net margin
-13086.5%−3728.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -41.5% | -24.9% | -0.6% | – | |
| Gross profit | -42.3% | -29.4% | – | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 57.2% | 197.9% | |
| Return on assets | – | -46.4% | -115.1% | |
| Current ratio | – | 5.40 | 0.83 | |
| Debt to equity | – | 23.09 | -0.21 | |
| Interest coverage | – | -21.3× | -8.6× | |
| Inventory turnover | – | – | 0.8× | |
| Capex to revenue | – | 187.9% | 19.5% | |
| Diluted shares | – | 1M | 10M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Clene generated $143.68M from operations and spent $6.90M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$143.68M
Used
$6.90M
Capital expenditure$6.90M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-13086.5%
×Asset turnover0.01×
×Equity multiplier-1.72×
=Return on equity, FY2025197.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -13086.5% | 0.01× | -1.72× | 197.9% |
| FY2024 | -11520.5% | 0.01× | 17.58× | -1738.4% |
| FY2023 | -7569.4% | 0.01× | 5.82× | -595.5% |
| FY2022 | -6325.2% | 0.01× | 6.79× | -377.9% |
| FY2021 | -1347.2% | 0.01× | 10.15× | -150.6% |
| FY2020 | -9357.8% | 0.00× | -1.23× | 57.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$26.17M
- Cash generatingOperating cash flow above zero-$18.55M
- Return on assets improvedROA up on the prior year-75.3% → -95.7%
- Earnings backed by cashOperating cash flow above net income-$18.55M vs -$26.17M
- Less leverageLong-term debt to assets fell16.9% → 20.6%
- Better liquidityCurrent ratio rose1.57 → 0.83
- No dilutionShare count did not rise7M → 10M
- Gross margin improvedGross margin up on the prior year79.53% → 78.50%
- More efficientAsset turnover rose0.01 → 0.01